MedTrace Logo

County Level Correlates of HPV Vaccine Series Completion Among Children Ages 11-14 Years in Indiana

NCT04576962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 122152

Last updated 2022-02-25

No results posted yet for this study

Summary

The overall objective is to document geographic variability in HPV vaccine series completion across the state of Indiana and to identify factors associated with low versus high rates of completion.

Objective a: To map HPV vaccine series completion rates across Indiana's 92 counties for children aged 14 years and younger. Hypothesis: The investigators expect wide variability in completion rates from county to county. Further, the investigators expect significantly less variability in county-level administration of vaccines required for middle-school entry (Tdap, MenACWY, and HepA vaccines).

Objective b: To identify county-level characteristics associated with HPV vaccine series completion rates across Indiana's 92 counties. Hypothesis: The investigators expect factors reflective of pragmatic obstacles to be associated with lower completion rates: such as lower population density, fewer primary health care providers (HCP) per capita, longer commute to work, lower median household income, and lower rates of insurance coverage of children.

Conditions

  • Human Papillomavirus Vaccination

Interventions

OTHER

Immunization Information System Review

Extraction of county- and state-level data on HPV vaccine completion from Indiana's Immunization Information System

Sponsors & Collaborators

Principal Investigators

  • Gregory D Zimet, PhD · Indiana University School of Medicine

Eligibility

Min Age
9 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-09
Primary Completion
2022-01-24
Completion
2022-01-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04576962 on ClinicalTrials.gov